EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says
Portfolio Pulse from Vandana Singh
Petros Pharmaceuticals (NASDAQ: PTPI) aims to transition its prescription erectile dysfunction (ED) therapy, Stendra (avanafil), to over-the-counter (OTC) status. This move could significantly expand the ED market, potentially tripling its size. The company is leveraging its expertise in the Rx-to-OTC switch market and has aligned with the FDA for a pivotal study review in 2H 2024.
June 17, 2024 | 7:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Petros Pharmaceuticals is focusing on transitioning its prescription ED therapy, Stendra, to OTC status. This could significantly expand the market and increase the company's revenue potential.
The transition of Stendra to OTC status could significantly increase market access and revenue for Petros Pharmaceuticals. The alignment with the FDA for a pivotal study review in 2H 2024 adds credibility to this potential growth.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100